Source: Hemp Supporter | Author: Hemp Supporter | Mar 24, 2021
We’re excited to announce the results of an important clinical study conducted by ValidCare on CBD: Preliminary results reveal no evidence of liver toxicity.
Since passage of the 2018 Farm Bill, the FDA has been investigating a pathway to regulate the sale of ingestible hemp-derived CBD products. Unfortunately, the agency has not taken any concrete steps, claiming that it needs more real-world data on CBD’s safety profile.
As part of the hemp industry’s continuing effort to provide FDA data, ValidCare commissioned a study and concluded that “preliminary findings show no evidence of liver disease in the 839 participants and no increase in the prevalence of elevated liver function tests when compared to a population with a similar incidence of medical conditions.”
Major kudos to ValidCare, as well as to the US Hemp Roundtable members who funded and participated in the study: American Shaman, CBD Distillery, Charlotte’s Web, Hemp Fusion, Kannaway and Medterra.
Evidence like this confirms that it is high time for FDA to legally recognize and regulate ingestible hemp-derived CBD products. That’s why it’s so important that Congress pass HR 841, which would establish a legal pathway for the sale of hemp-derived extracts as dietary supplements.
Please use our online portal to email your U.S. Representative today, urging him or her to co-sponsor HR 841.